Novel erythropoiesis-stimulating agents: A new era in anemia management

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 1, 2008, Pages 200-207

  Macdougall, Iain C ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY FAILURE; DRUG EFFECT; ERYTHROPOIESIS; HUMAN; REVIEW;

ANEMIA; ERYTHROPOIESIS; ERYTHROPOIETIN; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC;

EID: 38749115086     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03840907     Document Type: Short Survey

References (72)

1. Macdougall IC, Roberts DE, Coles GA, Williams JD: Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet 20: 99-113, 1991
2. Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z, et al.: Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 82: 7580-7584, 1985
3. Egrie JC, Grant JR, Gillies DK, Aoki KH, Strickland TW: The role of carbohydrate on the biological activity of erythropoietin. Glycoconj J 10: 263, 1993
4. Acharya VN, Sinha DK, Almeida AF, Pathare AV: Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis. J Assoc Physicians India 43: 539 -542, 1995
5. Bren A, Kandus A, Varl J, Buturovic J, Ponikvar R, Kveder R, Primozic S, Ivanovich P: A comparison between epoetin omega and epoetin alfa in the correction of anemia in hemodialysis patients: A prospective, controlled crossover study. Artif Organs 26: 91-97, 2002
6. Sikole A, Spasovski G, Zafirov D, Polenakovic M: Epoetin omega for treatment of anemia in maintenance hemodialysis patients. Clin Nephrol 57: 237-245, 2002
7. Spinowitz BS, Pratt RD: Epoetin delta is effective for the management of anaemia associated with chronic kidney disease. Curr Med Res Opin 22: 2507-2513, 2006
8. Kwan JT, Pratt RD: Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in pre-dialysis chronic kidney disease patients. Curr Med Res Opin 23: 307-311, 2007
9. Martin KJ, on behalf of the Epoetin Delta 3001 Study Group: Epoetin delta in the management of renal anaemia: Results of a 6-month study. Nephrol Dial Transplant 22: 3052-3054, 2007
10. Schellekens H: The first biosimilar epoetin: But how similar is it? Clin J Am Soc Nephrol 3: 174-178, 2008
11. The Court Service - Court of Appeal - Civil - Judgement: In TKT's technology, those cells were designated as R223 cells. Neutral Citation Number: [2002] EWCA Civ. 1096, 2002. Available at: http:// www.hmcourts-service.gov.uk/judgmentsfiles/j1329/Kirin_v_Hoechst.htm
12. Tangvoranuntakul P, Gagneux P, Diaz S, Bardor M, Varki N, Varki A, Muchmore E: Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci U S A 100: 12045-12050, 2003
13. Egrie JC, Browne JK: Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84: 3-10, 2001
14. Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, Busse L, Chang D, Fuller J, Grant J, Hernday N, Hokum M, Hu S, Knudten A, Levin N, Komorowski R, Martin F, Navarro R, Osslund T, Rogers G, Rogers N, Trail G, Egrie J: Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 21: 414 -421, 2003
15. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J: Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10: 2392-2395, 1999
16. Macdougall IC, Padhi D, Jang G: Pharmacology of darbepoetin alfa. Nephrol Dial Transplant 22[Suppl 4]: iv2-iv9, 2007
17. Macdougall IC: CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 4: 436-440, 2005
18. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, Dougherty FC, Reigner B: Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 1: 1211-1215, 2006
19. Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, Dougherty FC, BA 16528 Study Investigators: The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: Results of a phase II study. Clin Nephrol 67: 306-317, 2007
20. Locatelli F, Sulowicz W, Harris K, Selgas R, Kaufman J, Klinger M, Malberti F, Dougherty FC: SC C.E.R.A. (continuous erythropoietin receptor activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from SC epoetin 1-3 times per week in patients with CKD on dialysis [Abstract]. J Am Soc Nephrol 17: 619A, 2006
21. Jolling K, Perez Ruixo JJ, Hemeryck A, Vermeulen A, Greway T: Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin. Eur J Pharm Sci 24: 465-475, 2005
22. Long DL, Doherty DH, Eisenberg SP, Smith DJ, Rosendahl MS, Christensen KR, Edwards DP, Chlipala EA, Cox GN: Design of homogeneous, monopegylated erythropoietin analogs with preserved in vitro bioactivity. Exp Hematol 34: 697-704, 2006
23. Kochendoerfer GG, Chen SY, Mao F, Cressman S, Traviglia S, Shao H, Hunter CL, Low DW, Cagle EN, Carnevali M, Gueriguian V, Keogh PJ, Porter H, Stratton SM, Wiedeke MC, Wilken J, Tang J, Levy JJ, Miranda LP, Crnogorac MM, Kalbag S, Botti P, Schindler-Horvat J, Savatski L, Adamson JW, Kung A, Kent SB, Bradburne JA: Design and chemical synthesis of a homogeneous polymer-modified erythropoiesis protein. Science 299: 884-887, 2003
24. Chen SY, Cressman S: Mao F, Shao H, Low DW, Beilan HS, Cagle EN, Carnevali M, Gueriguian V, Keogh PJ, Porter H, Stratton SM, Wiedeke MC, Savatski L, Adamson JW, Bozzini CE, Kung A, Kent SB, Bradburne JA, Kochendoerfer GG: Synthetic erythropoietic proteins: Tuning biological performance by site-specific polymer attachment. Chem Biol 12: 371-383, 2005
25. Lee DE, Son W, Ha BJ, Oh MS, Yoo OJ: The prolonged half-lives of new erythropoietin derivatives via peptide addition. Biochem Biophys Res Commun 339: 380-385, 2006
26. Sytkowski AJ, Lunn ED, Risinger MA, Davis KL: An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties. J Biol Chem 274:24773-24778, 1999
27. Dalle B, Henri A, Rouyer-Fessard P, Bettan M, Scherman D, Beuzard Y, Payen E: Dimeric erythropoietin fusion protein with enhanced erythropoietic activity in vitro and in vivo. Blood 97: 3776-3782, 2001
28. Coscarella A, Liddi R, Bach S, Zappitelli S, Urso R, Mele A, De Santis R: Pharmacokinetic and immunogenic behavior of three recombinant human GM-CSF-EPO hybrid proteins in cynomolgus monkeys. Mol Biotechnol 10: 115-122, 1998
29. Coscarella A, Liddi R, Di Loreto M, Bach S, Faiella A, van der Meide PH, Mele A, De Santis R: The rhGM-CSF-EPO hybrid protein MEN 11300 induces anti-EPO antibodies and severe anaemia in rhesus monkeys. Cytokine 10: 964-969, 1998
30. Way JC, Lauder S, Brunkhorst B, Kong SM, Qi A, Webster G, Campbell I, McKenzie S, Lan Y, Marelli B, Nguyen LA, Degon S, Lo KM, Gillies SD: Improvement of Fc-erythropoietin structure and pharmacokinetics by modification at a disulfide bond. Protein Eng Des Sel 18: 111-118, 2005
31. Capon DJ, Chamow SM, Mordenti J, Marsters SA, Gregory T, Mitsuya H, Byrn RA, Lucas C, Wurm FM, Groopman JE, et al.: Designing CD4 immunoadhesins for AIDS therapy. Nature 337: 525-531, 1989
32. Yeh P, Landais D, Lemaitre M, Maury I, Crenne JY, Becquart J, Murry-Brelier A, Boucher F, Montay G, Fleer R, et al.: Design of yeast-secreted albumin derivatives for human therapy: Biological and antiviral properties of a serum albumin-CD4 genetic conjugate. Proc Natl Acad Sci U S A 89: 1904-1908, 1992
33. Bugelski P, Nesspor BT, Spinka-Doms T, Markopoulos D, Eirikis E, Fisher J, Volk A, Shamberger K, James I, Fisher P, Pool C, Jang H, Miller B, Huang C, Heavner G, Knight D, Ghrayeb J, Scallon B: Pharmacokinetics and pharmacodynamics of CTNO528, a novel erythropoiesis receptor agonist in normal and anemic rats. Blood 106: 146b, 2005
34. Franson KL, Burggraaf, Bouman-Trio EA, Cohen AF, Miller BE, Jang H, Marciniak SL, van de Ketterij EPS, Frederick B, Jiao, Q, Getsy J, Bald EH, Walker H, Schantz A, Ford JA, Mascioli K, Kowalchick JB: A phase I, single and fractionated, ascending dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietic mimetic antibody fusion protein, CTNO528 in healthy male subjects. Blood 106: 146b, 2005
35. Dumont JA, Bitonti AJ, Clark D, Evans S, Pickford M, Newman SP: Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J Aerosol Med 18: 294-303, 2005
36. Mitragotri S, Blankschtein D, Langer R: Ultrasound-mediated transdermal protein delivery. Science 269: 850-853, 1995
37. Maitani Y, Moriya H, Shimoda N, Takayama K, Nagai T: Distribution characteristics of entrapped recombinant human erythropoietin in liposomes and its intestinal absorption in rats. Int J Pharm 185: 13-22, 1999
38. Venkatesan N, Yoshimitsu J, Ohashi Y, Ito Y, Sugioka N, Shibata N, Takada K: Pharmacokinetic and pharmacodynamic studies following oral administration of erythropoietin mucoadhesive tablets to beagle dogs. Int J Pharm 310: 46-52, 2006
39. Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton NC, Dower WJ, Jolliffe LK, Wilson IA: Functional mimicry of a protein hormone by a peptide agonist: The EPO receptor complex at 2.8 A. Science 273: 464-471, 1996
40. Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett RW, Jolliffe LK, Dower WJ: Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273: 458-464, 1996
41. Fan Q, Leuther KK, Holmes CP, Fong KL, Zhang J, Velkovska S, Chen MJ, Mortensen RB, Leu K, Green JM, Schatz PJ, Woodburn KW: Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol 34: 1303-1311, 2006
42. Woodburn KW, Leuther K, Fan Q, Holmes C, Frederick B, Xu C, Wehrman T, Press R: Renal excretion is the primary route of elimination for the erythropoiesis stimulating agent Hematide as assessed by quantitative whole-body autoradioluminography (QWBA) in Sprague Dawley rats [Abstract SaP333]. Presented at the ERA-EDTA Congress; June 21-24, 2007; Barcelona, Spain
43. Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK, Woodburn KW, Schatz PJ, Okamoto DM, Naso R, Duliege AM: Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind placebo-controlled, dose-escalation study in healthy volunteers. Blood 108: 1830-1834, 2006
44. Macdougall IC, Tucker B, Yaqoob M, Mikhail A, Nowicki M, MacPhee I, Mysliwiec M, Sulowicz W, Zamauskaite A, Leong R, Iwashita J, Duliege AM, Wiecek A: Hematide, a synthetic peptide-based erythropoiesis stimulating agent, achieves correction of anemia and maintains hemoglobin in patients with chronic kidney disease not on dialysis [Abstract F-FC079]. Presented at the annual meeting of the American Society of Nephrology; November 14-19, 2006; San Diego, CA
45. Besarab A, Zeig S, Geronemus R, Pergola P, Whittier F, Zabaneh R, Schiller B, Kaplan M, Levin N, Wright S, Swan S, Wintz R, Wombolt D, Leong R, Lang W, Franco M, Duliege AM: Hematide™, a synthetic peptide-based erythropoiesis stimulating agent, maintains hemoglobin in hemodialysis patients previously treated epoetin alfa [Abstract 99]. Presented at the National Kidney Foundation Spring Clinical Meeting; April 10-14, 2007; Orlando, FL
46. Woodburn KW, Fan Q, Winslow S, Chen MJ, Mortensen RB, Casadevall N, Stead RB, Schatz PJ: Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp Hematol 35: 1201-1208, 2007
47. Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege A-M, Eckardt K-U: Treatment of anti-erythropoietin antibody-mediated pure red cell aplasia with Hematide. N Engl J Med 2008, in press
48. Pötgens A, Haberl U, Rybka A, Knorr K, Emgenbroich M, Casaretto M, Breuer B, Greindl A, Kessler C, Kromminga A, Frank H-G: An optimized supravalent EPO mimetic peptide with unprecedented efficacy. Ann Hematol 85: 643, 2006
49. Qureshi SA, Kim RM, Konteatis Z, Biazzo DE, Motamedi H, Rodrigues R, Boice JA, Calaycay JR, Bednarek MA, Griffin P, Gao YD, Chapman K, Mark DF: Mimicry of erythropoietin by a nonpeptide molecule. Proc Natl Acad Sci U S A 96: 12156-12161, 1999
50. Goldberg J, Jin Q, Ambroise Y, Satoh S, Desharnais J, Capps K, Boger DL: Erythropoietin mimetics derived from solution phase combinatorial libraries. J Am Chem Soc 124: 544-555, 2002
51. Bruegge K, Jelkmann W, Metzen E: Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-hydroxylases. Curr Med Chem 14: 103-112, 2007
52. Kivirikko KI, Myllyla R, Pihlajaniemi T: Protein hydroxylation: Prolyl 4-hydroxylase, an enzyme with four cosub-strates and a multifunctional subunit. FASEB J 3: 1609-1617, 1989
53. Baader E, Tschank G, Baringhaus KH, Burghard H, Gunzler V: Inhdbition of prolyl 4-hydroxylase by oxalyl amino acid derivatives in vitro, in isolated microsomes and in embryonic chicken tissues. Biochem J 300: 525-530, 1994
54. Safran M, Kim WY, O'Connell F, Flippin L, Gunzler V, Horner JW, Depinho RA, Kaelin WG Jr: Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: Assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci U S A 103: 105-110, 2006
55. Urquilla P, Fong A, Oksanen S, Leigh S, Turtle E, Flippin L, Brenner M, Muthukrishnan E, Fourney P, Lin A, Yeowell D, Molineaux C: Upregulation of endogenous EPO in healthy subjects by inhibition of HIF-PH [Abstract]. J Am Soc Nephrol 15: 546A, 2004
56. Wiecek A, Piecha G, Ignacy W, Schmidt R, Neumayer HH, Scigalla P, Urquilla P: Pharmacological stabilization of HIF increases hemoglobin concentration in anemic patients with chronic kidney disease [Abstract]. Nephrol Dial Transplant 20[Suppl 51: v195, 2005
57. Maxwell P: HIF-1: An oxygen response system with special relevance to the kidney. J Am Soc Nephrol 14: 2712-2722, 2003
58. Astellas Pharma Inc: Adverse Event of FG-2216 for the Treatment of Anemia [News release], May 7, 2007. Available at: http://http:// www.astellas.com/global/about/news/2007/pdf /070507_eg.pdf
59. Dame C, Sola MC, Lim K-C, Leach KM, Fandrey J, Ma Y, Kn6pfle G, Engel JD, Bungert J: Hepatic erythropoietin gene regulation by GATA-4. J Biol Chem 279: 2955-2961, 2004
60. Imagawa S, Yamamoto M, Miura Y: Negative regulation of the erythropoietin gene expression by the GATA transcription factors. Blood 89: 1430-1439, 1997
61. Nakano Y, Imagawa S, Matsumoto K, Stockmann C, Obara N, Suzuki N, Doi T, Kodama T, Takahashi S, Nagasawa T, Yamamoto M: Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease. Blood 104: 4300-4307, 2004
62. Barbone FP, Johnson DL, Farrell FX, Collins A, Middleton SA, McMahon FJ, Tullai J, Jolliffe LK: New epoetin molecules and novel therapeutic approaches. Nephrol Dial Transplant 14[Suppl 2]: 80-84, 1999
63. Shen SH, Bastien L, Posner BI, Chretien P: A protein-tyrosine phosphatase with sequence similarity to the SH2 domain of the protein-tyrosine kinases. Nature 352: 736-739, 1991
64. Klingmuller U, Lorenz U, Cantley LC, Neel BG, Lodish HF: Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80: 729-738, 1995
65. Akagi S, Ichikawa H, Okada T, Sarai A, Sugimoto T, Morimoto H, Kihara T, Yano A, Nakao K, Nagake Y, Wada J, Makino H: The critical role of SRC homology domain 2-containing tyrosine phosphatase-1 in recombinant human erythropoietin hyporesponsive anemia in chronic hemodialysis patients. J Am Soc Nephrol 15: 3215-3224, 2004
66. Fattori E, Cappelletti M, Zampaglione I, Mennuni C, Calvaruso F, Arcuri M, Rizzuto G, Costa P, Perretta G, Ciliberto G, La Monica N: Gene electro-transfer on an improved erythropoietin plasmid in mice and non-human primates. J Gene Med 7: 228-236, 2005
67. Rivera VM, Gao GP, Grant RL, Schnell MA, Zoltick PW, Rozamus LW, Clackson T, Wilson JM: Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 105: 1424-1430, 2005
68. Kakeda M, Hiratsuka M, Nagata K, Kuroiwa Y, Kakitani M, Katoh M, Oshimura. M, Tomizuka K: Human artificial chromosome (HAC) vector provides long-term therapeutic transgene expression in normal human primary fibroblasts. Gene Ther 12: 852-856, 2005
69. Schwenter F, Schneider BL, Pralong WF, Deglon N, Aebischer P: Survival of encapsulated human primary fibroblasts and erythropoietin expression under xenogeneic conditions. Hum Gene Ther 15: 669-680, 2004
70. Lippin Y, Dranitzki-Elhalel M, Brill-Almon E, Mei-Zahav C, Mizrachi S, Liberman Y, Iaina A, Kaplan E, Podjarny E, Zeira E, Harati M, Casadevall N, Shani N, Galun E: Human erythropoietin gene therapy for patients with chronic renal failure. Blood 106: 2280-2286, 2005
71. Takács K, Du Roure C, Nabarro S, Dillon N, McVey JH, Webster Z, Macneil A, Bartók I, Higgins C, Gray D, Merkenschlager M, Fisher AG: The regulated long-term delivery of therapeutic proteins by using antigen-specific B lymphocytes. Proc Natl Acad Sci USA 101: 16298-16303, 2004
72. Binley K, Askham Z, Iqball S, Spearman H, Martin L, de Alwis M, Thrasher AJ, Ali RR, Maxwell PH, Kingsman S, Naylor S: Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy. Blood 100: 2406-2413, 2002